A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

  1. Bardia, A.
  2. Hurvitz, S.A.
  3. Rugo, H.S.
  4. Brufsky, A.
  5. Cortes, J.
  6. Loibl, S.
  7. Piccart, M.
  8. Cowden, J.
  9. Spears, P.
  10. Carey, L.A.
Journal:
Future Oncology

ISSN: 1744-8301 1479-6694

Year of publication: 2021

Volume: 17

Issue: 30

Pages: 3911-3924

Type: Article

DOI: 10.2217/FON-2021-0868 GOOGLE SCHOLAR lock_openOpen access editor